Abstract

Text-Size + –

• We currently lack a prospective, randomized, multicenter trial, to reassure low-risk prostate cancer patients, especially younger ones, that watchful waiting is a legitimate treatment. To better manage these patients, we need to: first, confirm that the patient has low-risk prostate cancer; second, adapt the treatment to the risk (i.e., if therapy is chosen over watchful waiting, it should be monotherapy not multiple therapy); third, be aware of age migration; fourth, know that radical prostatectomy and radiation were shown to be very effective for these patients at 10-year follow-up; and lastly, make an effort to better define watchful waiting and embrace it more, to avoid overtreatment.